© 2004 by Oxford University Press
© 2004 Oxford University Press
ARTICLE |
Clustering of Gene Hypermethylation Associated With Clinical Risk Groups in Neuroblastoma
Affiliations of authors: Cancer Epigenetics Laboratory, Molecular Pathology Program, Spanish National Cancer Centre (CNIO), Madrid, Spain (MA, VD, ME); Department of Pediatrics (NKVC) and Department of Pathology (WLG), Memorial Sloan-Kettering Cancer Center, New York, NY
Correspondence to: Manel Esteller, MD, PhD, Cancer Epigenetics Laboratory, Spanish National Cancer Centre (CNIO), Melchor Fernandez Almagro 3, 28029 Madrid, Spain (e-mail: mesteller{at}cnio.es)
Background: Neuroblastoma is the most common extracranial solid malignancy in infancy and childhood, but the biological factors involved in its development and progression are still unclear. Transcriptional silencing of tumor suppressor genes mediated by hypermethylation of promoter CpG islands is a hallmark of human tumors. We addressed the clinical relevance of promoter hypermethylation in neuroblastoma. Methods: We examined the methylation status of 45 candidate genes representative of many cellular pathways in 10 neuroblastoma cell lines and of 10 of these genes in 145 tumor samples (118 of them were primary neuroblastomas). We used Fisher's exact test to examine the association of CpG island methylation and clinical subgroups and Kaplan–Meier analysis to determine the association between methylation and survival in primary tumors. Cluster analysis was used to group cell lines and tumors by gene methylation status. Bonferroni-corrected statistical tests were two-sided. Results: Clustering of neuroblastoma cell lines on the basis of hypermethylation distinguished lines with MYCN amplification (a negative prognostic factor) from those without it (P = .012). Promoter hypermethylation of the developmental gene HOXA9 was associated with mortality in noninfant patients (P = .04) and in tumors lacking MYCN amplification (P = .023). Hypermethylation of the proapoptotic gene TMS1 and the cell cycle gene CCND2 was associated with stage 4–progressing tumors (P<.001), but the genes were never methylated in stage 4S tumors, which undergo spontaneous regression. Hypermethylation of the differentiation gene RAR
2 was associated with patient survival (P = .032). Unsupervised hierarchical cluster analysis of all tumors based on methylation of the 10 genes separated several clinically relevant groups of tumors. Conclusions: Profiling the status of CpG island hypermethylation in human primary neuroblastomas may have clinicopathologic value.
CiteULike 
Connotea 
Del.icio.us What's this?
Editorial about this Article
- The Conundrum Posed by Cellular Heterogeneity in Analysis of Human Neuroblastoma
- Robert A. Ross and Barbara A. Spengler
J Natl Cancer Inst 2004 96: 1192-1193.[Extract] [Full Text] [PDF]
This article has been cited by other articles:
|
|
 |
|
  C. D E Margetts, M. Morris, D. Astuti, D. C Gentle, A. Cascon, F. E McRonald, D. Catchpoole, M. Robledo, H. P H Neumann, F. Latif, et al. Evaluation of a functional epigenetic approach to identify promoter region methylation in phaeochromocytoma and neuroblastoma Endocr. Relat. Cancer, September 1, 2008; 15(3): 777 - 786. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. Yang, C. M. Kiernan, Y. Tian, H. R. Salwen, A. Chlenski, B. A. Brumback, W. B. London, and S. L. Cohn Methylation of CASP8, DCR2, and HIN-1 in Neuroblastoma Is Associated with Poor Outcome Clin. Cancer Res., June 1, 2007; 13(11): 3191 - 3197. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. Reynolds, M. Sigaroudinia, G. Zardo, M. B. Wilson, G. M. Benton, C. J. Miller, C. Hong, J. Fridlyand, J. F. Costello, and T. D. Tlsty Tumor Suppressor p16INK4A Regulates Polycomb-mediated DNA Hypermethylation in Human Mammary Epithelial Cells J. Biol. Chem., August 25, 2006; 281(34): 24790 - 24802. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Bibikova, Z. Lin, L. Zhou, E. Chudin, E. W. Garcia, B. Wu, D. Doucet, N. J. Thomas, Y. Wang, E. Vollmer, et al. High-throughput DNA methylation profiling using universal bead arrays Genome Res., March 1, 2006; 16(3): 383 - 393. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Carr, E. Bell, A. D.J. Pearson, U. R. Kees, H. Beris, J. Lunec, and D. A. Tweddle Increased Frequency of Aberrations in the p53/MDM2/p14ARF Pathway in Neuroblastoma Cell Lines Established at Relapse Cancer Res., February 15, 2006; 66(4): 2138 - 2145. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. W. Laird Cancer epigenetics Hum. Mol. Genet., April 15, 2005; 14(suppl_1): R65 - R76. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Alaminos, V. Davalos, S. Ropero, F. Setien, M. F. Paz, M. Herranz, M. F. Fraga, J. Mora, N.-K. V. Cheung, W. L. Gerald, et al. EMP3, a Myelin-Related Gene Located in the Critical 19q13.3 Region, Is Epigenetically Silenced and Exhibits Features of a Candidate Tumor Suppressor in Glioma and Neuroblastoma Cancer Res., April 1, 2005; 65(7): 2565 - 2571. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Ross and B. A. Spengler The Conundrum Posed by Cellular Heterogeneity in Analysis of Human Neuroblastoma J Natl Cancer Inst, August 18, 2004; 96(16): 1192 - 1193. [Full Text] [PDF]
|
|